Rho kinase inhibitor (University of Gottingen/University of Ulm/Max-Planck Institute)

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug NameRho kinase inhibitor (University of Gottingen/University of Ulm/Max-Planck Institute)
Drug Alias NameRho kinase inhibitor (University of Gottingen/University of Ulm/Max-Planck Institute)amyotrophic lateral sclerosis therapeutics (University of Gottingen/MBM ScienceBridge)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionRhodopsin kinase inhibitors
TargetsRhodopsin kinase
Therapy Area/IndicationsAmyotrophic Lateral Sclerosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryGermany
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesUniversity Of Göttingen
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMax Planck Institut fur Experimentelle MedizinMBM ScienceBridge GmbHUlm University +[4] 
Active IndicationsN/A
Inactive IndicationsAmyotrophic Lateral Sclerosis

Other Information

ATC CodeN/A
Related LinksN/A